STATEN ISLAND, N.Y., Aug. 14, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial...
-Today at 07:02 am- MarketScreener
Related Keywords
United States ,Philadelphia ,Pennsylvania ,Netherlands ,Copenhagen ,Køavn ,Denmark ,America ,Holland ,Dutch ,Ursula Theuretzbacher ,Robertg Shawah ,Bob Deluccia ,Davidp Luci ,Kevin Garey ,Society Or Healthcare Epidemiology Of America ,Trial Oversight Committee ,Exchange Commission ,Nasdaq ,University Of Houston College Pharmacy ,Prnewswire Acurx Pharmaceuticals Inc ,European Congress ,Drug Administration ,Leiden University Medical Center Holland ,Infectious Disease Society Of America Boston ,Acurx Pharmaceuticals Inc ,Exchange Commission On Form ,Data Monitoring Committee ,Diseases Society Of America ,Acurx Pharmaceuticals ,Independent Data Monitoring Committee ,Annual European Congress ,Clinical Microbiology ,Infectious Disease ,Ibezapolstat Against ,Reduced Susceptibility ,Houston College ,Principal Investigator ,Acurx Executive Chairman ,World Antimicrobial Resistance Conference ,Infectious Disease Society ,Leiden University Medical Center ,Dutch Government ,Scientific Advisory Board ,Chief Executive Officer ,Chief Financial Officer ,Ibezapolstat Phase ,Bile Acid ,Clinical Practice Guidelines ,Diseases Society ,Healthcare Epidemiology ,New England Journal ,England Journal ,Private Securities Litigation Reform Act ,United States Food ,Chief Executive ,Markets ,
comparemela.com © 2020. All Rights Reserved.